hustleEveryDay
12 years ago
JMP Securities Raises Uroplasty to Outperform (UPI)
Uroplasty (NYSE: UPI) was upgraded by equities research analysts at JMP Securities from a “market perform” rating to an “outperform” rating in a research note issued to investors on Friday. The firm currently has a $6.00 price target on the stock, up from their previous price target of $5.60.
UPI has been the subject of a number of other recent research reports. Analysts at Roth Capital upgraded shares of Uroplasty from a “neutral” rating to a “buy” rating in a research note to investors on Tuesday, May 22nd. Separately, analysts at Dougherty & Co cut their price target on shares of Uroplasty from $6.50 to $5.00 in a research note to investors on Friday, March 30th. They now have a “buy” rating on the stock. Finally, analysts at Craig Hallum initiated coverage on shares of Uroplasty in a research note to investors on Tuesday, March 27th. They set a “buy” rating on the stock.
Uroplasty traded up 24.78% on Friday, hitting $4.18. The company’s market cap is $87.0 million.
Uroplasty, Inc. is a medical device company that develops, manufactures and markets products for the treatment of voiding dysfunctions.
mlkrborn
12 years ago
Uroplasty announces two new research and development initiatives to expand its commitment to using the co's neuromodulation technology to treat voiding dysfunctions (UPI) : "We will begin development of an implantable tibial nerve stimulator for the treatment of overactive bladder (OAB), and conduct a pilot study in the U.S. for the treatment of fecal incontinence using our Urgent PC Neuromodulation System," said David Kaysen, Chief Executive Officer and President of co. The development project, based on a patent the Company holds, of an implantable tibial nerve stimulator for the treatment of OAB is focused on securing a CE Mark for the European market. The Company expects the success of its Urgent PC Neuromodulation System, which delivers percutaneous tibial nerve stimulation (PTNS) by the temporary insertion of a needle electrode, will provide insight into the design and clinical elements of an implantable device. The implantable device will allow patients who initially respond to Urgent PC therapy administered in the doctor's office, to continue self-administering the therapy in the comfort of their homes. Beginning in the late summer of 2012, Uroplasty will conduct a pilot clinical trial in the U.S. for the treatment of fecal incontinence using its Urgent PC Neuromodulation System. Urgent PC already has a European CE Mark for the treatment of fecal incontinence and its clinical use, safety and effectiveness for treating this indication have been reported at scientific meetings and in worldwide peer-reviewed literature.